



Press release |

Regulated information

IBA signs two new *Proteus*[®]*ONE* contracts with Proton Partners International

- IBA to install two additional *Proteus*[®]*ONE* compact proton therapy solutions in the UK

Louvain-La-Neuve, Belgium, 13 December 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed two new contracts with Proton Partners International (PPI), to install two *Proteus*[®]*ONE** compact proton therapy solutions in Reading and an undisclosed site in the UK. The contracts are effective as of today.

The contracted *Proteus*[®]*ONE* solutions include Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making *Proteus*[®]*ONE* the only compact solution ready for adaptive treatment. The contracts also include a maintenance agreement. The typical end-user price for a *Proteus*[®]*ONE* solution with a maintenance contract is between EUR 35 and 40 million.

These new centers will be the fifth and sixth that IBA will install for PPI. Previously-ordered centers by PPI are currently being installed in Wales (Newport), in England (Northumberland and London) and in Abu Dhabi, UAE. These latest contracted *Proteus*[®]*ONE* will be the 15th and 16th installation of IBA's compact single-room proton therapy solution, globally. IBA has now sold 45 proton therapy centers worldwide. These projects are a result of the framework agreement with Philips that has been in place since September 2014, demonstrating the benefit of this relationship in bringing new international contracts to fruition.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted to partner with PPI, the institution that leads proton therapy penetration in UK and in the United Arab Emirates. PPI's choice of IBA and our compact solution demonstrates the increasing demand for this cutting edge treatment modality. At present, proton therapy represents only 1% of all radiotherapy treatments, however, studies estimate that 20% of patients treated by radiotherapy would benefit from being treated with proton therapy."

Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are very pleased to further expand our collaboration with IBA following the highly professional support and responsiveness that it has demonstrated to date. Cancer incidence is rising dramatically, globally, and more innovation is needed to deal with this disease. Our strategy of building a strong international network of proton therapy centers will guarantee high-quality treatment throughout our network, enabling more patients to benefit from cutting-edge proton therapy. Every cancer patient in UK deserves the best possible care without needing to travel far."



Press release |

Regulated information

ENDS

About *Proteus*[®]ONE

Proteus[®]ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. *Proteus*[®]ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. *Proteus*[®]ONE makes proton therapy easy.

* *Proteus*[®]ONE is the brand name of *Proteus*[®]235 in the US and Europe and a certified production Japan.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical officer to the company.

The Welsh Government's Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: www.proton-int.com

For further information, please contact:



Press release |

Regulated information

IBA

Jean-Marc Bothy

Chief Strategy Officer

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Jonathan Birt, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com